Colchicine CT results

PhaseEstimate optionsPatient groups (placebo/control)ResultsReferences
4Need for artificial ventilation, length of stay in intensive care, and mortalityIvermectin + colchicine + standard care—45; colchicine + standard care—45; standard care—45Colchicine was associated with clinically significant reductions in oxygen demand days, intensive care unit length of stay, and less mortality, while ivermectin added no beneficial effect.[115]
2Need for artificial lung ventilation, length of stay intensive therapy, mortality40/40Serum ferritin levels in most patients who received colchicine, returned to normal in contrast to the control group, whose serum ferritin levels remained high. Similarly, the mean CRP and D-dimer values after treatment among participants in the colchicine group were significantly lower than in the control group. Patients in the colchicine group stayed in the hospital for a shorter period compared with the control group.[116]
3Need for artificial lung ventilation, length of stay in intensive care, mortality36/36Colchicine reduced the duration of additional oxygen therapy and hospitalization. The drug was well tolerated. Since death was a rare event, one cannot argue that colchicine reduced COVID-19 mortality.[117]
3CTColchicine + standard therapy—89; standard therapy—63According to this study, colchicine can improve clinical outcomes and reduce pulmonary infiltration in patients with COVID-19.[118]
Not studied aboutInflammatory markers, mortalityColchicine + standard treatment—34; standard treatment—78Patients in the colchicine group had lower mortality rates, lower intubation rates, and a higher percentage of discharge.[119]
Not studied aboutLength of hospital stayColchicine + standard treatment—165; standard treatment—171The average length of hospital stay in the colchicine group was significantly short.[120]